BioTuesdays

Tag - Ben Haynor

AGP starts IceCure Medical at buy; PT $14.50

Alliance Global Partners launched coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $14.50. The stock closed at $8.61 on Sept. 21. IceCure has developed and markets the IceCure family of...

IMAC-Logo

AGP cuts IMAC to neutral; PT to $1.75 from $2.35

Alliance Global Partners downgraded IMAC Holdings (NASDAQ:IMAC) to “neutral” and reduced its price target to $1.75 from $2.35 after the Center for Medicare and Medicaid Services (CMS) requested repayment of $2.9-million...

Reshape-Lifesciences-Logo

AGP ups ReShape Lifesciences PT to $18.50 from $12

Alliance Global Partners raised its price target for ReShape Lifesciences (NASDAQ:RSLS) to $18.50 from $12, citing an improved outlook and lower-than-anticipated share count following it’s merger with Obalon...

myomo logo

AGP starts Myomo at buy; PT $36.50

Alliance Global Partners initiated coverage of Myomo (NYSEA:MYO) with a “buy” rating and price target of $36.50. The stock closed at $10.19 on June 9. “Myomo, in our view, represents one of the most compelling stories...

EyeGate Pharmaceuticals

AGP cuts EyeGate Pharma PT to $10.25 from $16.75

Alliance Global Partners reduced its price target for EyeGate Pharmaceuticals (NASDAQ:EYEG) to $10.25 from $16.75, citing a possible plan to sell additional common shares in the first half of this year in order to...

Sensus Healthcare Logo

AGP ups Sensus Healthcare PT to $7.50 from $2.95

Alliance Global Partners raised its price target for Sensus Healthcare (NASDAQ:SRTS) to $7.50 from $2.95, citing fourth quarter results that were well ahead of consensus estimates. The stock closed at $4.94 on March 1...

Reshape-Lifesciences-Logo

AGP starts ReShape Lifesciences at buy; PT $12

Alliance Global Partners initiated coverage of ReShape Lifesciences (OTCQB:RSLS) with a “buy” rating and price target of $12. The stock was quoted at $7.54 in afternoon trading on Feb. 18. ReShape is a rare pure-play in...

AGP starts Viveve Medical at buy; PT $10.75

Alliance Global Partners launched coverage of Viveve Medical (NASDAQ:VIVE) with a “buy” rating and price target of $10.75. The stock closed at $3.55 on Jan. 28. “After two disappointing, yet entirely explainable...